Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Critical issues in gene therapy commercialization

Nature Biotechnology volume 15, pages 689–690 (1997)Cite this article

Gene therapy faces the task of building an infrastructure that can connect with the mainstream.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Author information

Affiliations

  1. vice president for business administration at Argonex Inc., 2044 India Rd., Suite 202, Charlottesville, VA, 22901

    Aris Persidis

  2. managing director, Emerging Technologies Management Research Program, The Wharton School, University of Pennsylvania

    Michael S. Tomczyk

Authors
  1. Aris Persidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael S. Tomczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Persidis, A., Tomczyk, M. Critical issues in gene therapy commercialization. Nat Biotechnol 15, 689–690 (1997). https://doi.org/10.1038/nbt0797-689

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0797-689

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing